REGENXBIO (NASDAQ:RGNX) Research Coverage Started at Stifel Nicolaus

Stifel Nicolaus assumed coverage on shares of REGENXBIO (NASDAQ:RGNX – Free Report) in a research note released on Wednesday morning, Marketbeat Ratings reports. The firm issued a buy rating and a $35.00 target price on the biotechnology company’s stock. Several other brokerages also recently commented on RGNX. Wedbush reissued a neutral rating and issued a […]

Leave a Reply

Your email address will not be published.

Previous post Friendly Amy is passionate about writing
Next post Aprea Therapeutics’ (APRE) “Buy” Rating Reaffirmed at HC Wainwright